Kwak Minsun, Yeh Hye-Ryun, Yum Mi-Sun, Kim Hyun-Jin, You Su Jeong, Ko Tae-Sung
Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
Department of Pediatrics, Inje University Sanggye Paik hospital, Inje University College of Medicine, Seoul, Korea.
Korean J Pediatr. 2019 Mar;62(3):108-112. doi: 10.3345/kjp.2018.06730. Epub 2018 Sep 18.
Subacute sclerosing panencephalitis (SSPE) is a rare, progressive, and fatal central nervous system disorder resulting from persistent measles virus infection. Long-term data are scarce, with a maximum follow-up period of 10 years. Interferon-alpha (IFN-α) is a protein that exerts its antiviral activity via enhancement of cellular immune response and is reported to be an effective drug for the treatment of SSPE. However, there is currently no consensus regarding the optimal duration of IFN-α therapy. Here, we present a case report of a patient with SSPE treated with long-term intraventricular IFN-α therapy, which facilitated clinical improvement and neurological stabilization without causing serious adverse effects. To the best of our knowledge, this is one of the longest follow-up studies investigating a patient with SSPE receiving intraventricular INF-α treatment. Further studies are necessary to validate the benefits and safety of long-term intraventricular IFN-α treatment in patients with SSPE.
亚急性硬化性全脑炎（SSPE）是一种由持续性麻疹病毒感染引起的罕见、进行性且致命的中枢神经系统疾病。长期数据稀缺，最长随访期为10年。α干扰素（IFN-α）是一种通过增强细胞免疫反应发挥抗病毒活性的蛋白质，据报道是治疗SSPE的有效药物。然而，目前关于IFN-α治疗的最佳疗程尚无共识。在此，我们报告一例接受长期脑室内IFN-α治疗的SSPE患者，该治疗促进了临床改善和神经功能稳定，且未引起严重不良反应。据我们所知，这是对接受脑室内INF-α治疗的SSPE患者进行的最长随访研究之一。有必要进行进一步研究以验证长期脑室内IFN-α治疗对SSPE患者的益处和安全性。
